SARS-CoV-2 Infection in Children Less Than Forty Days Hospitalized in Belgium Between 2020 and 2022.

Autor: Demey M; From the Department of Paediatrics, Université libre de Bruxelles, Brussels, Belgium., Bruyneel A; Infection Prevention and Control Nurse (HOST)|Réseau Helora, CHU Tivoli, La Louvière, Belgium.; Health Economics, Hospital Management and Nursing Research Department, School of Public Health, Université libre de Bruxelles., Chatzis O; Paediatric Infectious Diseases Unit, Specialized Paediatrics Service, Department of Paediatrics, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium., Christiaens C; Department of Paediatric Infectious Diseases, CHC Montlegia, Liège, Belgium., Cossey V; Neonatal Intensive Care Unit, Infection Control Department, University Hospitals Leuven, Leuven, Belgium., De Crombrugghe G; From the Department of Paediatrics, Université libre de Bruxelles, Brussels, Belgium., De Lille L; Department of Paediatrics, O.L.V. van Lourdes Ziekenhuis Waregem, Waregem, Belgium., Goetghebuer T; Department of Paediatrics, CHU Saint-Pierre, Université libre de Bruxelles, Brussels, Belgium., Gueulette E; Department of Paediatrics, CHU UCL Namur - Site Saint Elisabeth, Namur, Belgium., Hainaut M; Department of Paediatrics, CHU Saint-Pierre, Université libre de Bruxelles, Brussels, Belgium., Heijmans C; Department of Paediatrics, Hôpital de La Louvière - Site Jolimont - HELORA, La Louvière, Belgium., Hubinont H; Department of Paediatrics, Hôpital Civil Marie Curie, Charleroi, Belgium., Lé PQ; Department of Paediatrics, Hôpital IRIS Sud, Site Etterbeek-Ixelles, Brussels, Belgium., Lecomte L; Department of Paediatrics, Hôpital de La Louvière - Site Jolimont - HELORA, La Louvière, Belgium., Mattijs I; Department of Paediatrics, AZ Delta, Roeselare, Belgium., Mignon C; Department of Paediatric Infectious Diseases, HUB Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Université libre de Bruxelles., Mondovits B; Department of Paediatrics, Clinique Saint-Jean., Rodesch M; Department of Paediatrics, HUB Hôpital Erasme, Université libre de Bruxelles., Rooze S; Pediatric Intensive Care Unit, HUB Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Université libre de Bruxelles, Brussels, Belgium., Schelstraete P; Department of Internal Medicine and Paediatrics, Ghent University Hospital, Ghent, Belgium., Stroobant D; Department of Paediatrics, Grand Hôpital de Charleroi, Charleroi, Belgium., Thielemans L; Department of Paediatrics, Sint-Maria Halle, Halle, Belgium., Thomas I; Department of Paediatrics, CHU Ambroise Paré, Mons, Belgium., Valbona SK; Department of Paediatrics, Clinique Saint-Jean., Van Damme E; Department of Paediatrics, ZNA Jan Palfijn, Merksem, Belgium., Van der Linden D; Paediatric Infectious Diseases Unit, Specialized Paediatrics Service, Department of Paediatrics, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium., Van Praet J; Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium., Vermeulen F; Pediatric Intensive Care Unit, HUB Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Université libre de Bruxelles, Brussels, Belgium., Weynants D; Department of Paediatrics, CHU UCL Namur - Site Saint Elisabeth, Namur, Belgium., Tilmanne A; Department of Paediatrics, Hôpital Civil Marie Curie, Charleroi, Belgium.; Department of Paediatrics, ZNA Jan Palfijn, Merksem, Belgium.; Department of Infectious Diseases, CHU Tivoli, La Louvière, Belgium.; Department of Infectious Diseases, Université libre de Bruxelles, Brussels, Belgium.

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2024 Sep 01; Vol. 43 (9), pp. e307-e309. Date of Electronic Publication: 2024 May 16.

A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.

Autor: Doijen J; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: JDoijen@its.jnj.com., Heo I; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: IHeo@its.jnj.com., Temmerman K; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KTemmer2@ITS.JNJ.com., Vermeulen P; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: PVERMEUL@its.jnj.com., Diels A; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: ADIELS@its.jnj.com., Jaensch S; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: SJAENSCH@its.jnj.com., Burcin M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: MBurcin@ITS.JNJ.com., Van den Broeck N; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: NVanden6@ITS.JNJ.com., Raeymaekers V; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: VRaeymae@ITS.JNJ.com., Peremans J; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: jpereman@ITS.JNJ.com., Konings K; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KKoning1@ITS.JNJ.com., Clement M; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mcleme12@its.jnj.com., Peeters D; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: DPEETER1@its.jnj.com., Van Loock M; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvloock@its.jnj.com., Koul A; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: AKOUL@its.jnj.com., Buyck C; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: CBUYCK@its.jnj.com., Van Gool M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvgool2@its.jnj.com., Van Damme E; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: evandamm@its.jnj.com.

Publikováno v: Antiviral research [Antiviral Res] 2024 Feb; Vol. 222, pp. 105789. Date of Electronic Publication: 2023 Dec 27.

Characteristics of Adolescents Admitted with Acute Alcohol Intoxication: A Retrospective Multicentre Study in Antwerp, Belgium, in the Period 2015-2021.

Autor: van Roozendaal H; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium., Verhulst S; Department of Paediatrics, Antwerp University Hospital, 2650 Edegem, Belgium., Glazemakers I; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.; University Centre for Child and Adolescent Psychiatry (ZNA-UKJA), 2020 Antwerp, Belgium., De Meulder F; Department of Paediatrics, GasthuisZusters Antwerpen (GZA), 2018 Antwerp, Belgium., Vander Auwera A; Department of Paediatrics, GasthuisZusters Antwerpen (GZA), 2018 Antwerp, Belgium., Bael A; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.; Department of Paediatrics, Hospital Network Antwerp (ZNA), 2020 Antwerp, Belgium., Van Damme E; Department of Paediatrics, Hospital Network Antwerp (ZNA), 2020 Antwerp, Belgium., Vlemincx I; Department of Paediatrics, General Hospital (AZ) Monica, 2100 Antwerp, Belgium., De Dooy J; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.; Department of Paediatrics, Antwerp University Hospital, 2650 Edegem, Belgium., van der Lely N; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.; Department of Paediatrics, Reinier de Graaf Hospital, 2625 AD Delft, The Netherlands., Van Hal G; Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium.

Publikováno v: Children (Basel, Switzerland) [Children (Basel)] 2023 Aug 12; Vol. 10 (8). Date of Electronic Publication: 2023 Aug 12.

Identification of Z-Tyr-Ala-CHN 2 , a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2.

Autor: Doijen J; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Temmerman K; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Van den Eynde C; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Diels A; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Van den Broeck N; Charles River Laboratories, Turnhoutseweg 30, 2340 Beerse, Belgium., Van Gool M; Janssen Cilag S.A., C/Jarama 75A, 45007 Toledo, Spain., Heo I; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Jaensch S; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Zwaagstra M; Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands., Diosa Toro M; Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands., Chiu W; Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium., De Jonghe S; Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium., Leyssen P; Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium., Bojkova D; Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany., Ciesek S; Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany., Cinatl J; Institute for Medical Virology, University Hospital, Paul-Ehrlich-Str. 40, Frankfurt University, 60596 Frankfurt am Main, Germany., Verschueren L; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Buyck C; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Van Kuppeveld F; Faculty of Veterinary Medicine, Yalelaan 1, Virology Division, Department of Biomolecular Health Sciences, Infectious Diseases and Immunology, Utrecht University, 3584 Utrecht, The Netherlands., Neyts J; Laboratory of Virology and Chemotherapy, Herestraat 49, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium., Van Loock M; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium., Van Damme E; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium.

Publikováno v: Microorganisms [Microorganisms] 2023 Mar 10; Vol. 11 (3). Date of Electronic Publication: 2023 Mar 10.

CENTRALIZATION DECISIONS IN MULTISIDED PLATFORM PORTFOLIOS.

Autor: TARZIJAN, JORGE (AUTHOR) Tarzijanjorge@gmail.com, SNIHUR, YULIYA (AUTHOR) Ysihur@iese.edu

Publikováno v: Academy of Management Perspectives. Aug2024, Vol. 38 Issue 3, p304-324. 21p. 3 Diagrams, 3 Charts.